Table 1.
Demographics of patient population.
| Characteristic | Overall, N = 401 | Comparison, N = 181 | Toci, N = 221 | p-value2 |
|---|---|---|---|---|
| Age | 60 (52, 65) | 60 (52, 63) | 62 (50, 66) | 0.5 |
| Gender | 0.6 | |||
| Female | 15 (38%) | 6 (33%) | 9 (41%) | |
| Male | 25 (62%) | 12 (67%) | 13 (59%) | |
| Race | >0.9 | |||
| Asian | 1 (2.5%) | 0 (0%) | 1 (4.5%) | |
| White | 39 (98%) | 18 (100%) | 21 (95%) | |
| Ethnicity | ||||
| Non-Hispanic | 40 (100%) | 18 (100%) | 22 (100%) | |
| Income Level | 0.3 | |||
| <$10,000 | 1 (2.8%) | 1 (5.9%) | 0 (0%) | |
| $10,001 - $25,000 | 4 (11%) | 0 (0%) | 4 (21%) | |
| $25,001 - $40,000 | 5 (14%) | 3 (18%) | 2 (11%) | |
| $40,001-$55,000 | 5 (14%) | 2 (12%) | 3 (16%) | |
| $55,001-$70,000 | 3 (8.3%) | 1 (5.9%) | 2 (11%) | |
| $70,001-$85,000 | 4 (11%) | 1 (5.9%) | 3 (16%) | |
| $85,001 - $100,000 | 5 (14%) | 4 (24%) | 1 (5.3%) | |
| >$100,000 | 9 (25%) | 5 (29%) | 4 (21%) | |
| Unknown | 4 | 1 | 3 | |
| Education Level | 0.6 | |||
| < 12 years | 1 (2.6%) | 0 (0%) | 1 (5.0%) | |
| High School | 9 (24%) | 4 (22%) | 5 (25%) | |
| Trade School | 3 (7.9%) | 2 (11%) | 1 (5.0%) | |
| Some College | 7 (18%) | 3 (17%) | 4 (20%) | |
| College Graduate | 7 (18%) | 3 (17%) | 4 (20%) | |
| Post Graduate Degree | 11 (29%) | 6 (33%) | 5 (25%) | |
| Unknown | 2 | 0 | 2 | |
| Primary diagnosis | 0.009 | |||
| Acute Lymphoblastic Leukemia | 4 (10%) | 1 (5.6%) | 3 (14%) | |
| Acute Myeloid Leukemia | 17 (42%) | 4 (22%) | 13 (59%) | |
| Chronic Myeloid Leukemia | 1 (2.5%) | 0 (0%) | 1 (4.5%) | |
| Chronic Myelomonocytic Leukemia | 3 (7.5%) | 1 (5.6%) | 2 (9.1%) | |
| Hodgkin Lymphoma | 5 (12%) | 5 (28%) | 0 (0%) | |
| Myelodysplastic Syndrome | 8 (20%) | 6 (33%) | 2 (9.1%) | |
| Non-Hodgkin Lymphoma | 2 (5.0%) | 1 (5.6%) | 1 (4.5%) | |
| Disease status at transplant | 0.024 | |||
| First Complete Remission (CR1) | 19 (48%) | 5 (28%) | 14 (64%) | |
| Other | 21 (52%) | 13 (72%) | 8 (36%) | |
| Karnofsky Performance Score | 0.048 | |||
| 70 | 3 (7.5%) | 2 (11%) | 1 (4.5%) | |
| 80 | 18 (45%) | 4 (22%) | 14 (64%) | |
| 90 | 13 (32%) | 7 (39%) | 6 (27%) | |
| 100 | 6 (15%) | 5 (28%) | 1 (4.5%) | |
| Graft source | 0.2 | |||
| Bone Marrow (BM) | 6 (15%) | 1 (5.6%) | 5 (23%) | |
| Peripheral Blood Stem Cell | 34 (85%) | 17 (94%) | 17 (77%) | |
| Prior autologous transplant | 0.005 | |||
| N | 34 (85%) | 12 (67%) | 22 (100%) | |
| Y | 6 (15%) | 6 (33%) | 0 (0%) | |
| Conditioning Regimen Type | 0.4 | |||
| Myeloablative (MAC) | 21 (52%) | 8 (44%) | 13 (59%) | |
| Reduced Intensity (RIC/NST) | 19 (48%) | 10 (56%) | 9 (41%) | |
| Highest Grade of aGVHD | 0.6 | |||
| I | 8 (20%) | 2 (11%) | 6 (27%) | |
| II | 3 (7.5%) | 2 (11%) | 1 (4.5%) | |
| III | 6 (15%) | 3 (17%) | 3 (14%) | |
| IV | 1 (2.5%) | 1 (5.6%) | 0 (0%) | |
| None | 22 (55%) | 10 (56%) | 12 (55%) | |
| aGVHD grade 2+ before day 28 | 2 (5.0%) | 0 (0%) | 2 (9.1%) | 0.5 |
1 Median (IQR); n (%).
2 Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test; Wilcoxon rank sum test with continuity correction.